DLL3 targeted therapy(NovaRock Biotherapeutics)

N/A

Report date: 2023/11/30 10:03:28

Base Information

Drug NameDLL3 targeted therapy(NovaRock Biotherapeutics)
Drug Alias NameN/A
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody
Mechanisms of ActionAnti-Delta-like protein 3
TargetsDelta-like protein 3
Therapy Area/IndicationsSmall Cell Lung Carcinoma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesNovarock Biotherapeutics Ltd
China Registration ClassN/A

Develop Information

Active CompaniesNovarock Biotherapeutics Ltd
Inactive CompaniesN/A
Active IndicationsSmall Cell Lung Carcinoma
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A